BIBvsSPDW
ProShares Ultra Nasdaq Biotechnology against SPDR Portfolio Developed World ex-US ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | SPDW | |
|---|---|---|
| Expense ratio | 0.95% | 0.030% |
| Assets | $96M | $41.2B |
| Net flow, 1 month | — | +$609M |
| Net flow, 1 year | −$11M | +$5.1B |
| Return, YTD | +41.4% | +10.8% |
| Return, 1 year | +70.7% | +13.6% |
| Avg daily volume | 8K | 3M |
| Holdings | 229 | 2480 |
| Listed | Apr 9, 2010 | Apr 20, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS